<DOC>
	<DOCNO>NCT01153698</DOCNO>
	<brief_summary>open , prospective , observational study collect data safety ( major bleed event ) efficacy ( symptomatic venous thromboembolism ( VTE ) ) switch Enoxaparin dabigatran etexilate patient total knee replacement ( TKR ) total hip replacement ( THR )</brief_summary>
	<brief_title>Pradaxa ( Dabigatran Etexilate ) VTE Prevention After Elective Total Hip Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : patient age 18 year undergo elective total hip knee replacement surgery Exclusion criterion : accord label recommendation Pradaxa 220 mg QD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>